China's National Medical Products Administration approved the importation of Roche Holding AG's Perjeta as a treatment for HER2-positive breast cancer, in combination with Herceptin and chemotherapy.

Perjeta, also known as pertuzumab, works by preventing the human epidermal growth factor receptor 2, or HER2, from pairing with other HER receptors on the surface of cancer cells. Binding of Perjeta to HER2 may also signal the immune system to destroy cancer cells.

Herceptin, also marketed by Roche, was included in China's national drug reimbursement list in 2017.